A股異動丨歐普康視放量跌超8% Q2淨利同比下滑
格隆匯8月8日丨歐普康視(300595.SZ)跌超8%,報45.95元,成交額放大至12.6億元,總市值411.6億元。公司上週五公吿,上半年主營收入6.84億元,同比上升20.05%;歸母淨利潤2.58億元,同比上升0.9%。其中,第二季度歸母淨利潤1.1億元,同比下降6.53%。公司主營產品的銷售和視光服務收入受疫情的影響較大,直接影響了公司2022年上半年度,尤其是第二季度的產品銷售和視光服務收入。中金公司點評稱,1H22利潤端低於市場預期,期待3Q快速恢復。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.